* Adventrx Pharmaceuticals Inc., of San Diego, reported 12-month stability test results performed on samples of Exelbine (vinorelbine injectable emulsion, ANX-530) were consistent with the stability data collected at six and nine months and would therefore support the company's new drug application, which it expects to submit in the fourth quarter. (See BioWorld Today, April 28, 2010.)
* Arcion Therapeutics, of Baltimore, said the FDA granted fast-track designation to ARC-4558 for the treatment of pain associated with painful diabetic neuropathy (PDN) following recently announced positive top-line results from a Phase IIb trial of ARC-4558 in adult patients with PDN. The firm also recently had an end-of-Phase II meeting with the agency. The ARC-4558 program is now poised to enter Phase …
Комментариев нет:
Отправить комментарий